Kimoks

Moxifloxacin, the active ingredient in Kimoks, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It exerts broad‑spectrum activity against Gram‑positive and Gram‑negative bacteria and is indicated for the treatment of several serious infections in adult patients, such as community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, skin and soft‑tissue infections, and intra‑abdominal infections.

GNH USA supplies Kimoks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines across European and global markets.

Moxifloxacin is used to treat bacterial infections affecting various organ systems.

Community‑acquired bacterial pneumonia: effective treatment of infection caused by susceptible pathogens in adult patients. Acute bacterial sinusitis: eradicates the causative bacteria and relieves sinus inflammation. Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load and improves respiratory symptoms. Skin and skin structure infections: combats Gram‑positive and Gram‑negative organisms in skin lesions. Intra‑abdominal infections: provides broad coverage for mixed bacterial flora in abdominal cavities.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Rash - Insomnia

Serious or Rare Side Effects: - Tendon rupture or tendonitis - QT interval prolongation and cardiac arrhythmias - Severe allergic reactions, including anaphylaxis - Clostridioides difficile‑associated diarrhea - Hepatic enzyme elevation or liver injury - Photosensitivity reactions

When prescribing moxifloxacin, clinicians should consider several safety precautions.

Renal impairment: assess renal function and adjust dose if required. History of tendon disorders: avoid use due to risk of tendonitis or rupture. Cardiac risk: monitor QT interval in patients with known prolongation or electrolyte disturbances. Pregnancy and lactation: use only if benefits outweigh potential risks. Concomitant medications: review for interactions that may affect cardiac rhythm or increase toxicity. Store at below 25°C: keep in original packaging, protect from moisture and light.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Co‑administration with other QT‑prolonging agents (e.g., quinidine, amiodarone, sotalol): may cause serious arrhythmias. - Concurrent use with systemic corticosteroids or NSAIDs: increased risk of tendon rupture. - Combination with antacids containing magnesium or aluminum, or with sucralfate: markedly reduces absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: increased plasma levels, monitor for toxicity. - Cyclosporine: may raise moxifloxacin concentrations, monitor renal function.